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Reactor concepts for human mesenchymal stem cell (hMSC) production are introduced. Thereby, special interest is laid on
the realization of these concepts as disposables fulfilling the GMP and PAT requirements. The specialty of the hMSC pro-
duction process is the cell itself being the product. This results in completely different process requirements compared to
e.g. protein production in mammalian cells. Thus, great attention has to be given to the shear sensitivity of the cells. The
cultivation and the harvest of the cells have to be very gentle to neither influence cell viability nor cell differentiability. Fur-
ther, the production process should not cause any undesirable cell changes. For hMSC production, cell harvest is the main
challenging process step. The reactor concepts should be suitable for hMSC production for clinical trials as ATMPs. There-
fore, disposable systems are especially applicable. The review describes more detailed bone marrow-derived hMSC produc-
tion in a disposable stirred tank reactor as promising reactor concept.
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1 Introduction
Human mesenchymal stem cells (hMSC) are an interesting
cell source for many applications. Besides their intensive
use in research, they gain more and more importance for
clinical applications. Especially in the field of regenerative
medicine and more precisely, in cell therapy hMSC are of
great interest. Clinical indications in which hMSC are pur-
suit include bone regeneration and cartilage repair, Crohn’s
disease as well as kidney or heart diseases [1 – 7]. Several
characteristics make hMSC an ideal candidate for cell ther-
apy approaches. Firstly, the ease of isolation and in vitro cul-
tivation is a significant advantage compared to other cell
types. Secondly, hMSC have been shown to control the in-
flammation process, cell death, fibrosis and tissue regenera-
tion [8]. In addition, the cells release growth factors, cyto-
kines and other signaling molecules which are often
sufficient for a therapeutic effect [8]. A specialty of hMSC is
immune modulation, which reduces immune response of
the patient even after allogenic cell therapy [9].
For a widespread application of hMSC a decisive role is
played by the cell quantity and quality. In vivo stem cells are
found in low numbers while large numbers are required for
clinical applications. The dosage of hMSC in therapeutic
applications depends on the type of indication and is gener-
ally not well defined. In adults the minimal therapeutic
hMSC dose is assessed with 1 – 2 · 106 hMSC per kg [10].
Furthermore, these cells have to be highly viable. In the last
few years early phase studies have indicated the safety of
autologous and allogenic hMSC. However, late-stage clinical
trials are ongoing and final results are still pending. Con-
trary to this progress, the cellular product manufacturing
including established and stable production processes, pro-
cess monitoring and quality control is still immature. To
commercialize hMSC products, the development of scalable
manufacturing solutions needs to be expedited.
Disposable reactor systems seem to be the ideal basis for
process development. The use of disposable bioreactor sys-
tems claims several advantages like simple and flexible pro-
cess handling, an increase in process safety by reduced inci-
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dence of cross-contaminations and a cost reduction through
lower personal demand and the disappearance of cleaning
processes [11 – 13]. Furthermore, disposable systems simpli-
fy process admission by the authorities since the validation
of cleaning in place (CIP) and sterilization in place (SIP) is
not necessary. An effortless transfer of standard systems to
geometrically similar disposable systems would be advanta-
geous. Problems arise due to the lack of experience in dispo-
sable systems concerning material quality [14] or potential
interactions with the products [15]. In addition, there is also
an increase in costs concerning waste disposable [16]. In the
following, available cultivation concepts for hMSC are
briefly summarized and details on disposable reactor con-
cepts are provided.
2 Process Requirements for Stem Cell
Expansion
Clinical use of hMSC as advanced therapy medical products
(ATMPs) underlies stringent quality control requirements.
These include a validated measurement of e.g. purity, differ-
entiability, and stability of the cells. Unfortunately, no avail-
able marker can fully define hMSC by itself today. The
Mesenchymal and Tissue Stem Cell Committee of the Inter-
national Society for Cellular Therapy has therefore defined
minimal criteria to characterize hMSC. According to their
definition hMSC are cells which are (i) plastic-adherent in
standard culture conditions, (ii) positive for CD105, CD73,
and CD90 and negative for CD45, CD34, CD14, or CD11b,
CD79a or CD19, and HLA-DR expression, and (iii) able to
differentiate into osteoblasts, adipo- and chondrocytes in
vitro [17]. Therefore, during process development for hMSC
expansion, product specifications must be maintained dur-
ing the process.
Stem cell manufacturing is further complicated by the de-
finition of the cell therapy approach. Therapies with autolo-
gous hMSC require other production facilities than allo-
genic cell products. Autologous therapy needs a small scale
manufacturing plant that can handle multiple samples from
individual patients without cross-contamination. Contrary,
allogenic cell products are bulk productions requiring large-
scale facilities. Furthermore, stem cell doses for many appli-
cations are not well defined. Currently cell number require-
ments for hMSC range from 1.5 up to 120 · 106 cells per
dose dependent on the indication [18].
The process development requires the identification of
critical parameters and quality features as well as the para-
meter definition and their connection to the cell product.
Afterwards, the process system can be designed, the strategy
for quality assurance can be developed and the methods for
process monitoring can be defined. Then the actual produc-
tion process could be established by development of routine
and reproducibility [19].
2.1 Suitable Growth Surfaces for hMSC
hMSC are strictly adherent cells, which need a suitable
growth surface. In some studies hMSC were grown in
aggregates in suspension [20]. However, hMSC change
their phenotype in these cultivations. In conclusion hMSC
growth as adherent cells on a cultivation surface is pre-
ferred. For cultivation in larger scale this growth surface
is mainly provided by multiray cell culture systems or by
carriers [14]. There are different kinds of microcarriers
(porous, non-porous, coated or not-coated), on which
hMSC have been shown to grow well and which enable
the maintenance of multipotency of hMSC [21]. These
consist of dextran, glass, gelatin, cellulose or other syn-
thetic polymers. In addition, the microcarrier surface is of-
ten modified with e.g. collagen for better cell attachment.
Besides cell growth, the surface has to assure hMSC adhe-
sion but also guarantee a gentle cell detachment. These
contradictory demands cannot be achieved by most com-
mercially available carrier types. Almost all carriers are
optimized for cell adhesion and growth but not for cell
detachment since this is not needed in vaccine or protein
production processes. For example, porous carriers have a
high surface to volume ratio and protect the cells against
shear forces but nutrient transfer and cell detachment are
poor [22]. Therefore non-porous carriers are favored for
hMSC expansion and have been described in the literature
[23]. From these carriers high quality hMSC can be har-
vested [24].
2.2 Inoculation and Harvest Strategies for hMSC
The inoculation strategy is crucial for stem cell adhesion.
Highest adhesion rates described in the literature were
usually achieved by a cyclic procedure with transient stirring
and resting phases [22, 25 – 28]. Inoculation densities ran-
ging from 1 to 3 · 104 cm–2 had only minor influence on the
efficiency of cell adhesion [29]. Regarding a constant final
cell density at the end of the process, the inoculation density
has an influence on the process efficiency as the expansion
factor is influenced. Therefore, the lowest inoculation den-
sity (≈ 0.6 · 103 cells/cm2) achieved the highest expansion
factor (≈ 7-fold) [25, 30].
The most challenging process part for high hMSC quality
and quantity is the cell harvest. In standard cell culture, dif-
ferent mechanical and enzymatically methods as well as a
combination of both have been described for cell detach-
ment. Mechanical detachment is very shear-intensive and
not suitable if the cell itself is the product. For enzymatic
detachment the selection of the enzyme is critical. Some of
the enzymes as the commonly used trypsin are aggressive
and could damage the cell surface proteins [31]. Further,
trypsin is available as cGMP grade but of costly nature. In
clinical use, hMSC are considered as ATMPs. Thus, the use
of animal derived products should be reduced due to safety
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as well as ethical concerns. Up to now, no harvest protocol
has been published for hMSC. The success of a harvest
strategy strongly varies with the carrier type, culture med-
ium and medium supplements, the hMSC source, and the
reactor system used.
2.3 Process Monitoring
As hMSC are regarded as ATMPs, they must go through
GMP regulations as well as requirements referred to pro-
cess analytical technology (PAT). PAT is regarded as a tool
for the design, analyses and control of production pro-
cesses. The final product quality can be ensured through
the measurement of process parameters and product char-
acteristics [32]. This includes an extensive online process
monitoring [33], which provides a useful tool for process
characterization and the detection of process changes.
However, basic knowledge of a link between various para-
meters and process procedure is sometimes missing. In
addition, kinetics and balances are difficult to determine
and describe. This means hMSC expansion processes are
difficult to control and reproduce [34]. In this respect, a
better process monitoring could accelerate the process de-
velopment and improve efficiency of the production pro-
cesses while ensuring high-quality products [35]. Further-
more, documentation of process data is necessary for
regulatory approval and the validation of a biopharmaceu-
tical process. Relevant parameters for the process charac-
terization are cell growth, cell quality, medium conditions
(temperature, pH, pO2 and pCO2) as well as metabolite
concentrations (glucose, lactate, glutamine and ammo-
nium) [36]. Temperature, pH, pO2 and pCO2 are routinely
controlled online in cell culture processes and probes are
available as disposables as well. Online monitoring of the
other process parameters in dynamic systems is not routi-
nely done today. For hMSC expansion in particular, the
online monitoring of cell growth and viability should be
satisfied. For this, the application of dielectric spectro-
scopy for biomass monitoring has been described in the
literature [37].
2.4 Balancing Nutrient Supply, System Homo-
geneity and Shear Forces
The adherent growing hMSC should be expanded and har-
vested in a preferably simple homogenous system with
low shear. In addition, the supply of the cells with nutri-
ents and oxygen must be incorporated into the system.
While unproblematic in static systems, this will be crucial
for dynamic systems especially at larger scales. Using a
stirred tank reactor, the maintenance and mixing of the
medium and the associated nutrient supply is realized by
the suitable stirrer speed. Stirring should be high enough
to distribute the hMSC on the microcarrier homogenously
during cell adhesion. Later in hMSC expansion process
stirring has to be optimized to avoid formation of large
cell-carrier aggregates. The formation of aggregates is dis-
advantageous because of the aggravation at the point of
cell harvest and a loss of cell viability. On the other hand,
the stirring speed should not have any negative influence
on the cells. In a perfused system (fixed-bed bioreactor),
shear forces are much lower and are determined mainly
by the superficial velocity.
hMSC are sensitive to high shear and respond with cell
detachment from the growth surface, reduced growth rate,
loss of viability and changes in expression [38]. Therefore,
oxygen supply should be realized with low shear. In static
systems, oxygen is supplied by surface aeration without
shear to the cells. In perfused systems, oxygenation is per-
formed outside of the reactor and therefore no shear is
imposed to the cells. In stirred systems, however, aeration
can cause shear forces in addition to the stirring itself.
Direct sparging via air bubbles can damage cells [39]. Exter-
nal or membrane aeration is more cell-preserving but
requires extended technical expenditure. A reduction of
shear in stirred systems can further be realized by pulsed
aeration based on an oxygen set point. This might be suffi-
cient for the oxygen supply of cell cultures depending on
cell line.
2.5 Economic Process Requirements
Besides the aforementioned concerns, economic reasons
need to be considered. The limited expandability of primary
hMSC demands an efficient process. To reduce expansion
process failures the process handling should be kept simple
and the risk of contamination should be minimized. The
number of vessels should be reduced to a minimum, result-
ing in a high surface to volume ratio. Preferably, production
should be performed in an automated closed reactor system.
Especially for expansion of autologous cells in clinical use
disposable reactor systems are favorable. These closed sys-
tems minimize cross-contamination between autologous
cells from different patients providing the cells for one
patient in one vessel. They are ready-to-use solutions with-
out any further preparation steps such as sterilization. For
clinical use reactor size for hMSC expansion is low (L-scale).
On the other hand, the safety and hygiene requirements
for therapeutic hMSC products are high. For the pro-
duction of allogenic hMSC, which is more like a bulk
production setup, disposables can be also preferable, be-
cause depended on production frequency and scale the
overall costs for disposable setup can be lower compared
to conventional production in stainless steel or glass reac-
tors.
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3 hMSC Expansion in Disposable Bioreactor
Systems
3.1 Expansion of hMSC in Static Systems
The cultivation of hMSC is typically performed statically in
standard systems like tissue culture flasks, culture trays,
roller bottles, gas permeable blood bags or multi-well plates
[19, 40, 41]. These mostly sterile disposable systems contain
standard plastic surfaces. Static cultivation is widely used in
research labs and many therapies and clinical trials have
been developed with cells expanded this way [42].
However, these culture vessels offer a limited scale-up
potential and little possibilities for process control and can-
not be automated easily. Furthermore, the process monitor-
ing of these systems requires sampling, which endangers
the system sterility [19]. In terms of cell characterization,
these systems enable an easy determination of growth rate
and metabolite kinetics because of simple sampling of med-
ia and cell detachment for cell count measurements. These
cultivation systems realize oxygen and nutrient supply by
diffusion through the culture media causing mass transport
limitations of nutrients, which can result in low cell densi-
ties. The low volume/surface ratio of these 2D systems is a
further disadvantage resulting in low time-space yield and
therefore a low process efficiency. Furthermore, the contam-
ination risk and high personal demand decrease the process
efficiency. Even though this production type might be ap-
propriate for autologous cell production due to the compara-
tively small number of cells required per patient, the need
of different efficient cultivation systems for mass produc-
tion of hMSC is obvious.
3.2 Expansion of hMSC in Dynamic Systems –
State of the Art
To overcome the limitations described in static cultivations
of hMSC, dynamic carrier based systems are being used,
but still limited to 200mL volumes in non-disposable spin-
ner flasks in most cases [24, 26, 30, 43 – 47].
Currently, different disposable dynamic bioreactor sys-
tems are commercially available, e.g., carrier-based spin-
ners, wave-mixed, orbitally shaken and stirred reactors, as
well as fixed-bed systems. As decades of knowledge in scale-
up and process development is available for these systems,
they are predestinated to being transferred to stem cell pro-
duction. These systems can be used with disposable and/or
standard online sensors for process monitoring. But com-
pared to the reusable systems, the commercial availability of
sensors or other reactor components is restricted [16]. In
contrast to the static systems, cells in these systems reach
much higher surface-to-volume ratios. A constant circula-
tion (perfusion) and mixing is ensured by stirring, wave
movement or rotation of the culture [40] enabling process
monitoring as demanded by PAT.
The simplest dynamic disposable systems described are
spinner flasks, usually used for process optimization be-
cause of their simple sampling procedure. However, in spin-
ner flasks a satisfactory online monitoring is not possible
and volumes of more than 1 L represent major exceptions
[30]. A different, but also simple system is the wave-induced
motion. First experiments of hMSC expansion on carrier in
a rocket-motion bioreactor (WAVE) have been described.
However, hMSC strongly agglomerated during the expan-
sion process in this interesting reactor concept [48].
Perfusion systems for 3-dimensional cultivation of hMSC
are fixed and fluidized bed reactors as well as wall-rotating
vessels. The reactors were partially filled with microcarriers
and perfused with media. These systems apply low shear,
which is advantageous when cultivating sensitive adherent
cells. Cell concentration is mostly measured indirectly by
the determination of glucose or oxygen consumption. Cell
sampling during the expansion process is not possible. Pro-
blematic is the formation of a metabolite gradient over the
reactor height. As well as the suspension systems, perfusion
systems can be automated. As an example an easy to
automate and low shear fixed-bed reactor system for geneti-
cally modified hMSC-TERT was described by Weber at al.
[23, 49 – 53]. The small scale of 20mL was realized as dispo-
sable system in syringes. Weber also described greater
volumes (up to 300-mL glass systems, offering 5500 cm2
growth surface), which are an ideal candidate for a new dis-
posable reactor system that is not commercially available
yet. In this process, key metabolites and the final cell num-
ber at the end of cultivation were used for offline monitor-
ing, resulting in a successful expansion process. Oxygen,
pH and temperature were used for online process monitor-
ing. Furthermore, the system has the advantage of being
one single system for the inoculation, cultivation and har-
vest to ensure sterility and a high surface to volume ratio.
The decisive disadvantage, however, is the inhomogeneity of
the fixed-bed system at larger scale. A strong variability was
observed concerning the cell growth and especially the har-
vest for cultivations in 300-mL fixed-bed volumes in stan-
dard configuration. This inhomogeneity makes an online
monitoring of cell growth directly in the fixed-bed difficult.
Another disadvantage is the performance of the flow rate in
the system. The flow rate has to be very low (v= 3 · 104 m s–1)
to maintain the cell quality which limits scale-up options.
Small stirred tank reactors with a larger volume than spin-
ner reactors are also available on the market as rigid systems
by two different companies: Sartorius Stedim (UniVessel®
SU) [54], and Merck-Millipore (Mobius™ CellReady) [55].
Both systems are compatible with various process control
units due to different motor adapters. The UniVessel is
equipped with two impellers, macrosparger, and disposable
sensors for pH and DO, whereas the Mobius™ CellReady 3L
bioreactor carries one marine impeller, micro- and macro-
sparger, no sensors, but a harvest port to the reactor bottom.
Cell growth conditions under low shear stress can be enabled
by the combination of bubble-free aeration and the use of
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appropriate impeller design. The ultimate benefit of the stir-
red tank reactor is the homogeneity of the system. This sim-
plifies the online monitoring of cell growth during the
whole process and allows an easy scale-up. A balance
between homogenous mixing, sufficient oxygen supply and
gentle cell handling must therefore be achieved.
3.3 Expansion of hMSCs in Dynamic Systems –
New Concepts
Based on an established process in a 3-L glass stirred tank
reactor with a model cell line (hMSC-TERT) the transfer of
the expansion process to disposables and primary hMSC is
introduced. hMSC-TERT cells (passage 68 – 84) are bone
marrow-derived, gene-modified cells, carrying the telomer-
ase reverse transcriptase (TERT) gene. This increases the
geno- and phenotypic stability of the cells without affecting
their differentiation potential [56]. In clinical trials, these
cells were used for allogenic cell therapy approaches [57].
For the established process, the transfer to disposable is
likely, as a geometric similar stirred system is available on
the market (Mobius™ CellReady 3L bioreactor). Especially
with regards to cell harvest and online monitoring of the
production process, the stirred tank reactor represents a pro-
mising solution [58 – 61].
The process in the glass stirred tank reactor was inocu-
lated with a density of 3000 – 7000 cells per cm2 growth sur-
face, which were grown before in T-flasks. The inoculation
strategy was performed in four adhesion cycles with stirring
(80 – 160 rpm) and subsequent resting phase. Key metabo-
lites and the final cell number, and also microscopic analy-
sis of the cells on the microcarriers were used for offline
monitoring because of the possibility of sampling during
the production process. Oxygen, pH, temperature and the
integrated permittivity measurement
via the dielectric spectroscopy were
used for online monitoring. Cells
were cultivated in 1.7 L of DMEM
with high glucose, which avoids an
exchange of culture medium and the
associated influence of the permittiv-
ity signal. For the cultivation, a
growth surface of 13 500 cm2 and a
cultivation time of six days were
used. The growth rate varied from
0.55 to 0.59 per day. At the end of the
cultivation, a cell density of around
50 000 cells per cm2 growth surface, a
total cells number up to 4 · 108 cells
per L of production volume, an ex-
pansion factor of 7.2 and a cell yield
after harvest of over 95% was deter-
mined. Quality control of the har-
vested hMSC-TERT showed high vi-
abilities and differentiability [60].
Aspects to be considered for the carrier-based process
transfer were the rotation speed, the aeration, the carrier
concentration, the reaction volume and according to PAT,
the possibility of process monitoring and control.
3.3.1 Transfer of hMSC-TERT Production Process in a
Disposable System
Cultivation parameters of the established cultivation process
of hMSC-TERT in a glass stirred tank reactor have been
used for the transfer to the geometric similar disposable re-
actor (Mobius™ CellReady 3L bioreactor, Merck-Millipore).
All parameters were kept constant except the stirrer speed,
which was reduced to 60 rpm because of the change in stir-
rer diameter based on tip-speed calculation. The data of an
expansion are shown in Fig. 1. A cell density of 3000 –
7000 cells/cm2 (growth surface = 14 500 cm2) was used to
inoculate the disposable reactor, also performed in cyclic
mode. Compared to an expansion process performed with
allogeneic cells, the inoculation density used is higher
because of the availability of a sufficient number of cells
(autologous) and the possibility to minimize process time.
During 6 days of cultivation, the stirrer speed was stepwise
increased to 90 rpm to prevent cell agglomeration. Neverthe-
less, cell agglomeration occurred (Fig. 1a) indicating non-
optimal culture conditions. The growth rates of 0.53 d–1
were comparable to the hMSC-TERT expansion in the glass
tank. At the end of cultivation, cell harvest was performed
by the use of an external sieve and a cell density of
48 500 cells/cm2 growth surface, a total cells number of
4.1 · 108 cells per L of production volume, an expansion fac-
tor of 6.9 and a cell yield after harvest of over 99% was
determined. Thus, a successful transfer of hMSC-TERT pro-
duction process into the disposable system could be shown.
Further optimization of the process is needed to reduce the
Chemie
Ingenieur
Technik
Chemie Ingenieur Technik 2013, 85, No. 1–2, 67–75 © 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.cit-journal.com
b
a
Figure 1. Expansion of hMSC-TERT in a disposable stirred tank reactor. The process was per-
formed in a Mobius™ CellReady 3L bioreactor (Millipore) filled with RapidCell® carrier (MP
Biomedicals). As cultivation medium DMEM-HG with 2mM glutamine was used. Temperature
was set to 37 °C, pH to 7.2. hMSC-TERTwere inoculated with 3000– 7000 cells/cm2 and grown
for 6 days under continuous stirring (60 – 90 rpm). Two different cultivations are exemplary
shown ( and ). Cell growth was determined offline via a florescence assay [37]. At the end
of the cultivation, cells were harvested with an external device using trypsin. a) SYBR green
staining of carrier grown with hMSC-TERT after 6d cultivation; b) SYBR green staining of car-
rier after harvest of hMSC-TERT.
Stem cell production 71
aggregate formation to guarantee an equal quality of the
harvested cells.
3.3.2 Production Process for Primary hMSC in a
Disposable System
After successfully realizing the production process for the
model cell line hMSC-TERT in a disposable reactor, expan-
sion of primary bone marrow-derived hMSC was investi-
gated. It is assumed that primary cells react differently com-
pared to continuous cell lines [14]. To evaluate this for
primary hMSC, the impact of the cultivation conditions was
determined by gene expression analysis. Therefore, hMSC,
which were grown before on cell culture surfaces, were cul-
tivated on collagen-coated SoloHill microcarriers either sta-
tically in T-flask or dynamically in the Mobius™ CellReady
3L bioreactor and compared to a standard cultivation of
hMSC as monolayer in T-flasks. Prelimitary tests showed
that best growth and harvest efficiency of primary hMSC
was investigated by collagen-coated Solohill microcarriers.
The agitation of the microcarriers (Fig. 2b) had the smallest
effect compared to shearing cells in a device (data not
shown) or the change from microcarrier culture to flask
culture (Fig. 2a). The difference between flask culture and
microcarrier generated 17 genes that were differentially
regulated five times into three independent cell lines. To
prove the functionality of the hMSC, dynamically cultivated
cells were analyzed. hMSC taken from dynamic culture
showed similar surface markers and differentiation capacity
when compared to hMSC taken from the static culture.
The gene expression and functional analysis indicated that
an expansion of primary hMSC in a disposable stirred tank re-
actor could give viable cells in a comparable quality as the
standard static cultivations. The data of an expansion are
shown in Fig. 3. A Mobius™ CellReady 3L bioreactor was in-
oculated with 800 primary hMSC per cm2. In this case a low
cell number is used for inoculation associated with an ex-
tended cultivation time because of the limitation of available
autologous cells for expansion process. Growth surface in the
reactor was provided by a collagen-coated carrier (SoloHill).
At the beginning of the expansion process the growth surface
was 5400 cm2. During expansion the surface was increased to
10 800 cm2 at day 7 and 12 960 cm2 until process end. No spe-
cial inoculation was performed; cells adhered well during
slow stirring (35 rpm). During 12 days of cultivation, the stir-
rer speed was increased to 55 rpm and 75rpm subsequently.
The increase in stirrer speed was combined with a medium
feed (1 L DMEM-LG after 7 d, 0.4 L DMEM-HG after 11 d).
This fed-batch strategy gave a 6-time higher expansion factor
when compared to batch cultivations (data not shown).
Although the cell distribution on the carrier was quite
inhomogeneous especially at the cultivation beginning
(Fig. 3a), the primary bone marrow-derived hMSC grew fast
and did not agglomerate very strong. The growth rates of
the hMSC fed-batch expansion were 0.45 to 0.53 d–1. Com-
pared to the hMSC-TERT, expansion growth rates were
comparable. Final cell density at the end of the expansion
was 49 750 cells/cm2 growth surface with a total cell number
of 2.7 · 108 cells per L reaction volume (Fig. 3) and an expan-
sion factor of 62. The expanded primary hMSC maintained
their differentiability (Fig. 4). These results showed that
mass of primary hMSC can be successful produced in a
dynamic disposable reactor system.
3.3.3 SystemModification for Process Optimization
The described disposable bioreactor requires an additional
unit to allow cell harvest. To simplify the harvesting proce-
dure and to minimize the contamination risk, the disposa-
ble reactor was modified. A stainless steel sieve in a polycar-
bonate construction was inserted into the bioreactor system
(Fig. 5). This modification allows the separation of the cells
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Figure 2. Impact of growth surface and cultivation system on hMSC gene expression. For gene expression analysis, hMSC were cultivated,
harvested and frozen. mRNA und microarray analysis (Affymetrix Gene Chip Human Gene 1.0 ST) of the cells were performed by Precision
Biotech (Illinois). a) Comparison of different growth surfaces. Primary hMSC were cultivated on collagen-coated plastic surfaces in T-flasks
or on collagen-coated SoloHill microcarriers for 2 days in DMEM-LG containing 10%MSC-qualified FBS (LifeTech), 2mM glutamine und
8ng rFGF2. b) Comparison of non-agitated and agitated cultivation. Primary hMSC were cultivated on SoloHill microcarriers for 2 days in
DMEM-LG containing 10%MSC-qualified FBS (LifeTech), 2mM glutamine und 8ng rFGF2. Cultivation was done in low-adhesion petri
dishes (static) or in a Mobius™ CellReady 3L bioreactor (dynamic).
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from the carriers after cell harvest. So cell
detachment can be performed in the ster-
ile reactor containment and the harvested
cells can be pumped out of the reactor. At
the end, the cell inoculation, expansion
and harvest could be combined in one sin-
gle disposable system [62]. Furthermore,
the cell harvest within the reactor would
allow the monitoring and control of the
harvesting process according to PAT by di-
electric measurement. Thereby, the enzy-
matic incubation time could be reduced to
aminimum to avoid cell damage.
4 Conclusion
Over the last few years, it has been no-
ticed that a commercial realization of cell
therapy cannot succeed without a parallel
development of manufacturing strategies
for the therapeutic cells. The current expansion methods
used in research or clinical trials are unsuitable for a repro-
ducible, safe and controlled hMSC expansion with reason-
able effort. Many academic and industrial groups work on
process strategies and reactor concepts for hMSC expan-
sion. Especially the use of disposable technologies seems to
be promising for this application. Even though the advan-
tages of disposable are convincing, long-term tests to proof
material quality and exclude unwanted interactions with the
product have to be done. Also availability of probes for
online process control as disposables has to be ensured.
First studies have shown that both autologous and allo-
genic hMSC can be grown under dynamic and controlled
conditions on microcarriers without losing viability and
potency. Cultivations of hMSC-TERT in the glass bioreactor
and the disposable system were comparable in cell yield. A
higher expansion factor of cells compared to literature has
been investigated [63]. However, in literature the cultivation
was implemented with primary hMSC, a different inocula-
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Figure 3. Expansion of primary hMSC in a disposable stirred tank reactor. The process was
performed in a Mobius™ CellReady 3L bioreactor (Millipore) filled collagen-coated carrier
(SoloHill). As cultivation medium DMEM-LG with 2mM glutamine, 10%MSC-qualified
FBS (LifeTech) and 8ng rFGF2 was used. The temperature was set to 37 °C, pH to 7.2. hMSC
were inoculated with 800 cells/cm2 and grown for 12d under continuous stirring (35 –
75 rpm). Two different cultivations are exemplary shown ( and ). The arrows indicate
the feed with medium and carrier (1 L medium and 15g carrier at day 7, 0.4 L medium and
6g carrier at day 10). Cell growth was determined offline. DAPI staining of carrier grown
with primary hMSC after a) 2 days cultivation; b) 8 days cultivation.
Figure 4. Differentiation potential of cultivated hMSC. Primary
hMSC were cultivated dynamically in the Mobius™ CellReady 3L
bioreactor or statically in T-flasks for 7d in DMEM-LG containing
10%MSC-qualified FBS (LifeTech), 2mM glutamine und 8ng
rFGF2. After cultivation, the cells were harvested and differen-
tiated into adipocytes. Lipid droplets in the cells were stained
with oil-red-o and analyzed via microscopy. Undifferentiated
primary hMSC served as controls.
pO2, pH, T
sampling port
O2
external membrane 
module internal sieve
Figure 5. Modification of the
Mobius™ CellReady 3L bioreac-
tor to simplify cell harvest. The
reactor was modified with an in-
ternal sieve to separate the car-
riers from the cells after cell har-
vest. Further, in addition to sur-
face and microsparger aeration
was performed bubble-free
aeration via an external mem-
brane module which decreased
shear forces in the reactor.
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tion density and a cultivation time of five days. As shown in
[62] for autologous hMSC expansion the fed-batch-strategy
combined with a low inoculation density gave the highest
expansion factor. This extremely high expansion factor
depended on the low inoculation density and was paid with
a long process time. Total cell yield and cell number per cm2
at the end of the primary hMSC expansion process was
similar to allogenic hMSC-TERT expansion. So the superior-
ity of an expansion strategy cannot only be discussed with
the expansion factor but also with the process time, total cell
yield and process costs. The disposable stirred tank system
seems to be very suitable for the GMP production of high
quality hMSC in high yield. It could be shown that the high
process requirements for hMSC expansion have been com-
plied in a disposable reactor system.
Nevertheless, besides the reactor system itself, further im-
provement needs to be done concerning basic cultivation
tools for hMSC. For example, commercially available car-
riers are missing, which are exclusively optimized for cell
adhesion. The possibility of cell harvest, which is imperative
in hMSC expansion, is thereby not considered. Cell harvest
from carriers is of little relevance for mammalian cell cul-
ture processes providing only few harvest strategies that are
possibly adaptable to hMSC expansion process. Further, the
optimal culture conditions for hMSC are hardly defined.
Due to a lack in an absolute determination of hMSC quality
it is almost impossible to truly investigate the impact of the
cultivation parameters.
This means that research concerning hMSC production
strategies and quality control urgently need to be further
intensified. Unfortunately, in the past, these fields were
mostly neglected. At the end, the reliability of hMSC manu-
facturing is significantly involved in the success of cell ther-
apy. Without an effective manufacturing strategy cell ther-
apy cannot be profitable.
Symbols used
A [cm2] surface area
c [mmol L–1] concentration
l [mm] length
m [ng, kg] weight
n [rpm] rotation spped
t [d] time
V [mL, L] volume
m [m s–1] superficial velocity
pCO2 [bar] partial pressure of carbon dioxide
pO2 [bar] partial pressure of oxygen
T [°C] Temperature
l [d–1] specific average growth rate
lmax [d
–1] specific maximal growth rate
Abbreviations
ATMP advanced therapy medicinal product
cGMP current good manufacturing practice
CIP cleaning in place
DMEM Dulbecco’s modified eagle medium
DO dissolved oxygen
FBS fetal bovine serum
GMP good manufacturing practice
HG high glucose
hMSC human mesenchymal stem cells
LG low glucose
PAT process analytical technology
rFGF2 recombinant fibroblast growth factor 2
SIP sterilization in place
TERT telomerase reverse transcriptase
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